Merck KGaA / DE0006599905
10.02.2025 - 20:06:25Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition
| EQS-Ad-hoc: Merck KGaA / Key word(s): Takeover 10-Feb-2025 / 20:06 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Darmstadt, February 10, 2025 – Merck KGaA (“Merck”) reacts to press reports and confirms advanced discussions with Springworks Therapeutics, Inc. Merck also confirms that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met. End of inside information Contact Merck KGaA Dr. Gangolf Schrimpf Merck KGaA Frankfurter Straße 250 64293 Darmstadt Germany Phone: +49 6151 729591 Email: gangolf.schrimpf@merckgroup.com Internet: https://www.merckgroup.com/ ISIN: DE0006599905 WKN: 659990 Indices: DAX Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX End of Inside Information 10-Feb-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Merck KGaA |
| Frankfurter Str. 250 | |
| 64293 Darmstadt | |
| Germany | |
| Phone: | +49 (0)6151 72 - 2702 |
| E-mail: | insiderregister@merckgroup.com |
| Internet: | https://www.merckgroup.com/de |
| ISIN: | DE0006599905 |
| WKN: | 659990 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX |
| EQS News ID: | 2084015 |
| End of Announcement | EQS News Service |
| |
2084015 10-Feb-2025 CET/CEST
